Clinical Trials Browser

Active not recruiting × regorafenib × Head & Neck × Clear all

NCT02657551 2025-09-11

A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer

Phase 2 Active not recruiting

8 enrolled 10 charts

Thyroid Neoplasms